Cargando…
The cost-effectiveness of prostate cancer screening using the Stockholm3 test
OBJECTIVES: The European Randomized Study of Screening for Prostate Cancer found that prostate-specific antigen (PSA) screening reduced prostate cancer mortality, however the costs and harms from screening may outweigh any mortality reduction. Compared with screening using the PSA test alone, using...
Autores principales: | Karlsson, Andreas A., Hao, Shuang, Jauhiainen, Alexandra, Elfström, K. Miriam, Egevad, Lars, Nordström, Tobias, Heintz, Emelie, Clements, Mark S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906342/ https://www.ncbi.nlm.nih.gov/pubmed/33630863 http://dx.doi.org/10.1371/journal.pone.0246674 |
Ejemplares similares
-
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study
por: Hao, Shuang, et al.
Publicado: (2022) -
Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022) -
Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019) -
The economic burden of prostate cancer – a Swedish prevalence-based register study
por: Hao, Shuang, et al.
Publicado: (2020) -
Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS)
por: Olsson, Henrik, et al.
Publicado: (2020)